scholarly journals THE INNOVATIONS, ADVANCES AND OUTLOOKS OF LIQUID BIOPSY IN ONCOLOGY: A LITERATURE REVIEW

2018 ◽  
Vol 2 (4) ◽  
pp. 117-128
Author(s):  
Antonio Marlos Duarte de Melo ◽  
Messias Silvano Da Silva Filho ◽  
Bárbara Torquato Alves ◽  
Kevellyn Cruz Aguilera ◽  
Ana Maria Correia Alencar ◽  
...  
Keyword(s):  
Literature Review ◽  
Liquid Biopsy ◽  
Residual Disease ◽  
Diagnostic Technique ◽  
Clinical Aspects ◽  
Malignant Neoplasms ◽  
Non Invasive ◽  
Need To Evaluate ◽  
Peripheral Blood Plasma ◽  
Diagnosis Of Cancer

Studies on the biology of cancer are multiplying and have been giving significant repercussions on the care of cancer patients, and there is a growing need to evaluate the biology of the tumor. Conventional tissue biopsies currently represent the gold standard in the diagnosis of cancer, but they are not suitable for serial analysis because of the need for invasive procedures, besides being able to present a high risk of life and also impossibility of reaching surgical in some tumors. To solve this obstacle, the use of the Liquid Biopsy, which analyzes the presence of biomarkers released by cancer cells, such as circulating tumor cells (CTCs), tumor cell DNA (ctDNA) and exosomes is being discussed. These techniques are non-invasive or minimally invasive and collect their samples from peripheral blood, plasma and serum, urine, saliva and cerebrospinal fluid (CSF). As they are already being used in the treatment of several histopathological types of cancer, these new techniques generally represent a revolution in the understanding of early diagnosis, choice of personalized treatment, follow-up of the treatment response in real time, detection of minimal residual disease and prognosis for malignant neoplasms. The objective of this study was to present a literature review to clarify the fundamental molecular and clinical aspects involved in this revolutionary diagnostic technique by extracting the data from the sample. Keywords: Liquid Biopsy. Oncology.: literature review

Upconversion nanoparticle and gold nanocage satellite assemblies for sensitive ctDNA detection in serum

The Analyst ◽  
2020 ◽  
Vol 145 (16) ◽  
pp. 5553-5562
Author(s):  
Jiawei Wang ◽  
Guanping Hua ◽  
Lihuang Li ◽  
Danyang Li ◽  
Fanfan Wang ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Diagnostic Technique ◽  
Circulating Tumor Dna ◽  
Molecular Diagnostic ◽  
Non Invasive ◽  
Timely Diagnosis ◽  
Diagnosis Of Cancer ◽  
Biopsy Methods ◽  
Clinically Significant ◽  
Tumor Dna

A rapid molecular diagnostic technique targeting circulating tumor DNA (ctDNA) has become one of the most clinically significant liquid biopsy methods for non-invasive and timely diagnosis of cancer.

Total microfluidic platform strategy for liquid biopsy

2020 ◽  
pp. 1-25
Author(s):  
Sehyun Shin
Keyword(s):  
Liquid Biopsy ◽  
Residual Disease ◽  
Future Research ◽  
Microfluidic Platforms ◽  
Liquid Biopsies ◽  
Related Area ◽  
Detailed Review ◽  
Non Invasive ◽  
Clinical Benefits ◽  
Minimal Residual

A liquid biopsy is a simple and non-invasive biopsy that examines a range of information about a tumor through a simple blood sample. Due to its non-invasive nature, liquid biopsy has many outstanding clinical benefits, including repetitive sampling and examination, representation of whole mutations, observation of minimal residual disease etc. However, liquid biopsy requires various processes such as sample preparation, amplification, and target detection. These processes can be integrated onto microfluidic platforms, which may provide a sample-to-answer system. The present review provides a brief overview of liquid biopsies, a detailed review of the technologies in each process, and prospective concluding remarks. Through this review, one can have a basic but cross-disciplinary understanding of liquid biopsy, as well as knowledge of new starting points for future research in each related area.

scholarly journals Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3284
Author(s):  
Arnaud Martel ◽  
Stephanie Baillif ◽  
Sacha Nahon-esteve ◽  
Lauris Gastaud ◽  
Corine Bertolotto ◽  
...  
Keyword(s):  
Natural History ◽  
Anterior Chamber ◽  
Gold Standard ◽  
Liquid Biopsy ◽  
Current Knowledge ◽  
The Other ◽  
Non Invasive ◽  
History Of ◽  
Diagnosis Of Cancer ◽  
The One

Tissue biopsy is considered the gold standard when establishing a diagnosis of cancer. However, tissue biopsies of intraocular ophthalmic malignancies are hard to collect and are thought to be associated with a non-negligible risk of extraocular dissemination. Recently, the liquid biopsy (LB) has emerged as a viable, non-invasive, repeatable, and promising way of obtaining a diagnosis, prognosis, and theragnosis of patients with solid tumors. LB refers to blood, as well as any human liquid. The natural history of uveal melanoma (UM) and retinoblastoma (RB) are radically opposed. On the one hand, UM is known to disseminate through the bloodstream, and is, therefore, more accessible to systemic venous liquid biopsy. On the other hand, RB rarely disseminates hematogenous, and is, therefore, more accessible to local liquid biopsy by performing an anterior chamber puncture. In this review, we summarize the current knowledge concerning LB in UM, RB, conjunctival tumors, and choroidal metastases. We also develop the current limitations encountered, as well as the perspectives.

scholarly journals ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1989
Author(s):  
Laura Escudero ◽  
Francisco Martínez-Ricarte ◽  
Joan Seoane
Keyword(s):  
Cerebrospinal Fluid ◽  
Brain Cancer ◽  
Liquid Biopsy ◽  
Therapeutic Strategy ◽  
Residual Disease ◽  
Imaging Techniques ◽  
Prognostic Information ◽  
Tumour Heterogeneity ◽  
Diagnosis And Prognosis ◽  
Cns Malignancies

The correct characterisation of central nervous system (CNS) malignancies is crucial for accurate diagnosis and prognosis and also the identification of actionable genomic alterations that can guide the therapeutic strategy. Surgical biopsies are performed to characterise the tumour; however, these procedures are invasive and are not always feasible for all patients. Moreover, they only provide a static snapshot and can miss tumour heterogeneity. Currently, monitoring of CNS cancer is performed by conventional imaging techniques and, in some cases, cytology analysis of the cerebrospinal fluid (CSF); however, these techniques have limited sensitivity. To overcome these limitations, a liquid biopsy of the CSF can be used to obtain information about the tumour in a less invasive manner. The CSF is a source of cell-free circulating tumour DNA (ctDNA), and the analysis of this biomarker can characterise and monitor brain cancer. Recent studies have shown that ctDNA is more abundant in the CSF than plasma for CNS malignancies and that it can be sequenced to reveal tumour heterogeneity and provide diagnostic and prognostic information. Furthermore, analysis of longitudinal samples can aid patient monitoring by detecting residual disease or even tracking tumour evolution at relapse and, therefore, tailoring the therapeutic strategy. In this review, we provide an overview of the potential clinical applications of the analysis of CSF ctDNA and the challenges that need to be overcome in order to translate research findings into a tool for clinical practice.

Gender budgeting in public financial management: a literature review and research agenda

2021 ◽  
pp. 002085232110317
Author(s):  
Tobias Polzer ◽  
Isabella M Nolte ◽  
Johann Seiwald
Keyword(s):  
Literature Review ◽  
Financial Management ◽  
Secondary Data ◽  
Analytical Framework ◽  
Political Agenda ◽  
Future Research ◽  
Ex Post ◽  
Ex Ante ◽  
Need To Evaluate ◽  
Gender Budgeting

Gender budgeting calls for including a gender perspective at all levels of governmental budgetary processes. While the literature on gender budgeting is interdisciplinary and covers a wide geographical range, it remains fragmented. This study uses a literature review to examine the current discourse on gender budgeting and to elicit avenues for future research. Our review shows that studies focus either on emerging economies, such as India or South Africa, or on countries in Europe. Drawing on an analytical framework, we find that most studies scrutinize the ex ante stages of gender budgeting, whereas less is known about the concurrent and ex post stages. Moreover, because little is known about the outcome and impact of gender budgeting, governments do not know what instruments function best in different settings. Given their ex ante focus, most studies on gender budgeting often either remain descriptive or analyse secondary data. Despite scholars from different disciplines contributing to the field of gender budgeting, several ‘blank spots’ remain, particularly in public sector accounting. Points for practitioners While current gender budgeting projects tend to focus on the ex ante stage of gender budgeting, future practitioner attention needs to focus on the equally important concurrent and ex post stages, which have received less attention thus far. An increasing number of governments worldwide are implementing gender budgeting projects. Governments need to evaluate the outcome and impact of these projects in a timely fashion, aiming at reducing structural inequalities related to gender. Gender budgeting is willingly adopted in times of prosperity and stability or when the scope of projects appears manageable. To avoid negative impacts on their achievements, policy makers need to put gender budgeting on the political agenda and institutionalize it in times of instability and crisis.

Infections due to Vagococcus spp. Microbiological and clinical aspects and literature review

2021 ◽  
Author(s):  
Laura Racero ◽  
Claudia Barberis ◽  
Germán Traglia ◽  
María Susana Loza ◽  
Carlos Vay ◽  
...  
Keyword(s):  
Literature Review ◽  
Clinical Aspects

scholarly journals Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3373
Author(s):  
Milena Matuszczak ◽  
Jack A. Schalken ◽  
Maciej Salagierski
Keyword(s):  
Prostate Cancer ◽  
Liquid Biopsy ◽  
Current Knowledge ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Cost Effective ◽  
Non Invasive ◽  
Diagnosis And Prognosis

Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA) level in the blood serum. PSA is a marker produced by prostate cells, not just cancer cells. Therefore, an elevated PSA level may be associated with other symptoms such as benign prostatic hyperplasia or inflammation of the prostate gland. Due to this marker’s low specificity, a common problem is overdiagnosis, which leads to unnecessary biopsies and overtreatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, there is no doubt that the improvement of the current procedure by applying effective, sensitive and specific markers is an urgent need. Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document